Meusinvest (Noshaq)

Ampacimon SA specializes in manufacturing dynamic line rating systems for transmission and distribution system operators globally. Founded in 2010 and headquartered in Grace-Hollogne, Belgium, with an additional office in Cumming, Georgia, the company offers a range of innovative products designed to enhance grid infrastructure. These include ADR View, a modeling tool that utilizes historical weather data; ADR Sense, a self-powered vibration sensor; and ADR Operate, a real-time data-acquisition engine that retrieves crucial operational parameters. Additionally, Ampacimon provides ADR Trend and ADR Horizon for short- and medium-term ampacity forecasting. These solutions enable grid operators to anticipate congestion issues and implement cost-effective reconfiguration strategies, thereby addressing challenges related to aging infrastructure, congestion, and the integration of renewable energy sources.

RISORCE fills a need in Belgium for local solutions for processing tire waste while remaining dedicated to a circular economy strategy. We provide a regionally-based, technologically and environmentally sound solution.

IVEX is a start-up originating from the University of Leuven, specializing in the development of tools and software designed for the testing and validation of advanced driver assistance systems (ADAS) and autonomous vehicles. The company comprises a diverse team and has established partnerships with global firms, notably Siemens, to enhance its growth in the high-tech sector. IVEX offers a cloud-based suite of testing and validation tools alongside an onboard real-time safety checker, which can function independently or in conjunction with other systems. Its solutions streamline the analysis of extensive driving data, enabling engineers to efficiently identify and categorize driving scenarios, create digital representations for simulation, and assess safety performance while minimizing computational resource usage. By focusing on safety and efficiency, IVEX aims to support the industry's need for reliable and effective validation of automated driving technologies.

Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacture of small satellites equipped with advanced sensors. The company focuses on creating satellite imagery technology that captures high-resolution optical data, allowing for frequent data collection. In addition to satellite production, Aerospacelab develops tools that utilize artificial intelligence and machine learning to automate various tasks, facilitating processes such as surveying and monitoring. This innovative approach enables customers to efficiently analyze substantial volumes of data and optimize the extraction of valuable insights from the information gathered.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Ampacimon SA specializes in manufacturing dynamic line rating systems for transmission and distribution system operators globally. Founded in 2010 and headquartered in Grace-Hollogne, Belgium, with an additional office in Cumming, Georgia, the company offers a range of innovative products designed to enhance grid infrastructure. These include ADR View, a modeling tool that utilizes historical weather data; ADR Sense, a self-powered vibration sensor; and ADR Operate, a real-time data-acquisition engine that retrieves crucial operational parameters. Additionally, Ampacimon provides ADR Trend and ADR Horizon for short- and medium-term ampacity forecasting. These solutions enable grid operators to anticipate congestion issues and implement cost-effective reconfiguration strategies, thereby addressing challenges related to aging infrastructure, congestion, and the integration of renewable energy sources.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

e-peas SA is a Belgian company that specializes in designing and manufacturing electronic systems that enable energy autonomy for Internet of Things (IoT) applications. Founded in 2014 and based in Mont-Saint-Guibert, the company develops energy harvesting solutions that allow IoT devices to draw power from their environment, including sources such as solar, thermal, vibration, and radiofrequency. e-peas produces energy harvesting power management integrated circuits (PMICs) and low-power microcontrollers that enhance the performance and longevity of batteries in connected devices. By facilitating the efficient use of ambient energy, e-peas aims to reduce the need for frequent battery replacements across various sectors, including home automation, healthcare, and agriculture. The company's innovations contribute to making IoT devices smarter and more energy-efficient, ultimately striving for a future where devices can operate indefinitely without traditional power sources.

Hyloris Pharmaceuticals SA is a specialty pharmaceutical company based in Liege, Belgium, founded in 2013. The company focuses on reformulating well-known pharmaceuticals to enhance their value within the healthcare system. Hyloris develops proprietary products that aim to address unmet medical needs, providing significant advantages over existing alternatives. Its product portfolio includes cardiovascular treatments for conditions such as atrial fibrillation, congestive heart failure, and coronary heart disease, as well as a range of formulations including intravenous ready-to-use and oral liquid products, along with topical gels and creams. Currently, Hyloris has two early commercial-stage products: Sotalol IV for atrial fibrillation and Maxigesic IV, a non-opioid analgesic.

IVEX is a start-up originating from the University of Leuven, specializing in the development of tools and software designed for the testing and validation of advanced driver assistance systems (ADAS) and autonomous vehicles. The company comprises a diverse team and has established partnerships with global firms, notably Siemens, to enhance its growth in the high-tech sector. IVEX offers a cloud-based suite of testing and validation tools alongside an onboard real-time safety checker, which can function independently or in conjunction with other systems. Its solutions streamline the analysis of extensive driving data, enabling engineers to efficiently identify and categorize driving scenarios, create digital representations for simulation, and assess safety performance while minimizing computational resource usage. By focusing on safety and efficiency, IVEX aims to support the industry's need for reliable and effective validation of automated driving technologies.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Convert Pharmaceuticals SA, founded in 2017 and based in Saint-Gilles, Belgium, focuses on the development of hypoxia-activated cytotoxic small molecules for cancer treatment. As a clinical phase I-IIa drug development company, Convert Pharmaceuticals is building a proprietary pipeline that targets tumor microenvironment-specific factors to enhance therapeutic outcomes. The company's lead product is a hypoxia-activated prodrug (HAP), designed to overcome the challenges posed by hypoxia, which often leads to resistance against conventional anti-cancer therapies. By integrating proprietary insights into the tumor microenvironment with advanced drug and biomarker development expertise, Convert Pharmaceuticals aims to provide effective and well-tolerated treatment options for cancer patients.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Preesale is a mobile-based ticket management application designed for event organizers to efficiently manage events and sell tickets. Founded in 2015 and based in Liege, Belgium, Preesale differentiates itself by allowing organizers to access cash flows before their events, enhancing revenue generation and targeting qualified leads. The application integrates seamlessly with Facebook, enabling users to create and sell tickets in under five minutes. Additionally, it provides analytical tools to track sales, facilitates communication with guests through text messages, and offers a smartphone-based ticket scanning feature for event entry. Overall, Preesale aims to improve visibility and accessibility to events, streamlining the ticketing process for both organizers and attendees.

2 Observe is a company focused on observational research and the validation of innovative concepts within the biotechnology and private healthcare sectors. Established in 2010, it aims to address unmet needs in patient care by developing effective solutions that enhance quality of life. The company leverages the expertise of its founders, who come from diverse backgrounds in the medical community, research, and the life sciences industry. It specializes in patient monitoring technologies that provide continuous supervision of high-risk patients. These technologies alert healthcare providers in real-time, such as notifying nurses when a patient exits their bed or experiences complications related to respiratory failure, thereby ensuring that patients receive attentive and timely care.

XDC S.A. operates as a Pan-European digital cinema service company. It manages operations for the deployment of digital cinema systems in theatres; and prepares and delivers digital content, which is distributed in cinemas, as well as manufactures digital cinema products, including servers, theatre management systems, projections systems, and central libraries. The company's products include CineStore Systems, a suite of digital cinema solutions; The CineStore Solo G3, a hybrid digital cinema server that offer JPEG 2000 and MPEG-2 play-back capabilities; The CineStore Audi, a device, which provides digital to analogue conversion, external analogue audio source inputs, and signal isolation; The CineStore Plaza, a hardware and software suite that enables its users to manage a cinema multiplex from a single point, as well as 3D digital cinema. XDC S.A. also provides digital content lab for the whole production, post-production, and distribution chain, as well as to synchronize various sounds and subtitle versions on the master; key management and archiving; network operations centre, which includes a spare parts logistical strategy centre and a NOC equipment centre; and XDC Entertainment, a content delivery platform to alternative content distributors/providers. The company was founded in 2004 and is based in Liège, Belgium with additional offices in Belgium, Germany, Spain, and France.